New Two-Pronged attack on Tough-to-Treat leukemia begins human testing
NCT ID NCT07411586
Summary
This early-stage trial aims to find a safe and effective dose of two oral drugs, olutasidenib and ziftomenib, used together. It is for adults with a hard-to-treat, relapsed form of acute myeloid leukemia (AML) that has two specific genetic mutations (NPM1 and IDH1). The study will first determine the best dose and then see if that dose can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.